Sanofi ADR
USUSDSanofi ADR (MI:1SAN) — Biotechnology: Pharmaceutical Preparations. Antal børser, hvor selskabets aktier handles: 6. På denne side — kurs og diagram, udbytte, største aktionærer og historik over antal aktier.
Om virksomheden
- Websted
- sanofi.com
- Sektor
- Health Care · Biotechnology: Pharmaceutical Preparations
- Hovedkontor
- PARIS, France
- Administrerende direktør
- Paul Hudson
- Ansatte
- 106 566
- Grundlagt
- 2004
- Børsnoteret siden
- 24.07.2006 (MI:1SAN)
- Udestående aktier
- 1.22 mia. pr. 2025-12-31
- Free float
- 2.16 mia.
- Markedsværdi
- 98.67 mia. USD
- Insidere
- 0%
- Institutionelle investorer
- 8.02%
- Branche (SIC)
- Pharmaceutical Preparations
- Juridisk form
- QVPB
- ISIN
- FR0000120578
- LEI
- 549300E9PC51EN656011
- Udbetalingsgrad
- 0%
- FCF
- 10.8 mia. EUR
- Gæld
- 18.7 mia. EUR1.0 år FCF
- Udbyttestreak
- 23 år
- Indtjening, FCF og udbetalt udbytte — for de 12 måneder frem til 31.12.2025 (selskabets seneste rapport).
Beskrivelse
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Børser og tickere
| Børs | Ticker | Valuta | Pris | Type |
|---|---|---|---|---|
| US USA Stocks | SNYNF OTC | USD | 78.99 -1.19% | almindelige aktier |
| LSE London Stock Exchange | 0O59 IOB | EUR | 71.63 +0.72% | almindelige aktier |
| MI Borsa Italiana (Milan) | 1SAN sekundær | EUR | 71.64 +0.90% | almindelige aktier |
| PA Euronext Paris | SAN primær | EUR | 71.52 +0.83% | almindelige aktier |
| VI Vienna Stock Exchange | SANO sekundær | EUR | 71.3 +1.03% | almindelige aktier |
| XETRA Xetra | SNW sekundær | EUR | 71.78 -1.21% | almindelige aktier |
Udbytte
Sanofi ADR (1SAN) udbetaler udbytte én gang om året. I løbet af de sidste 12 måneder blev der betalt 4.12 EUR pr. Aktie (betalinger: 1). Det svarer til cirka 5.75% af den nuværende aktiekurs. Baseret på betalingshistorikken forventes næste ex-udbyttedato omkring 04.05.2027. Uafbrudt udbyttehistorik: 23 år.
| Ex-dato | Udbetaling | Beløb | % | Type | Ticker |
|---|---|---|---|---|---|
| 2026-05-05 | 2026-05-07 | 4.1200 EUR | 5.8/5.8 % | årlig | MI:1SAN |
| 2025-05-12 | 2025-05-14 | 3.9200 EUR | 5.5/5.5 % | årlig | MI:1SAN |
| 2024-05-13 | — | 3.7600 EUR | 5.2/10.2 % | årlig | MI:1SAN |
| 2023-05-30 | — | 3.5600 EUR | 5.0/5.0 % | årlig | MI:1SAN |
| 2022-05-06 | — | 3.3300 EUR | 4.6/4.6 % | årlig | MI:1SAN |
Nyheder denne uge
Endnu ingen nyheder fra virksomhedens websted.
Største ejere
| Ejer | Andel | Aktier | Rapportdato |
|---|---|---|---|
| Dodge & Cox Inc. | 10.54% | 28.09 mio. | 2026-06-30 |
| Dodge & Cox Funds-Dodge… | 7.84% | 20.9 mio. | 2026-06-30 |
| Morgan Stanley | 4.02% | 10.7 mio. | 2026-06-30 |
| Fisher Asset Management,… | 3.99% | 10.63 mio. | 2026-06-30 |
| Bank of America Corporat… | 3% | 8.01 mio. | 2026-06-30 |
| Invesco Ltd. | 2.55% | 6.8 mio. | 2026-06-30 |
| JPMORGAN CHASE & CO | 2.47% | 6.57 mio. | 2026-06-30 |
| Mondrian Investment Part… | 2.07% | 5.52 mio. | 2026-06-30 |
| Brandes Investment Partn… | 1.55% | 4.14 mio. | 2026-06-30 |
| AIM Sector Funds (Invesc… | 1.51% | 4.03 mio. | 2026-04-30 |
| Federated Hermes, Inc. | 1.44% | 3.85 mio. | 2026-06-30 |
| Boston Partners | 1.44% | 3.84 mio. | 2026-06-30 |
| VANGUARD STAR FUNDS-Vang… | 1.31% | 15.85 mio. | 2026-07-31 |
| Putnam ETF Trust-Putnam… | 1.26% | 3.36 mio. | 2026-05-31 |
| VANGUARD TAX-MANAGED FUN… | 0.87% | 10.53 mio. | 2026-06-30 |
| iShares Trust-iShares Co… | 0.67% | 8.11 mio. | 2026-08-31 |
| Dodge & Cox Funds-Dodge… | 0.63% | 1.67 mio. | 2026-06-30 |
| AMERICAN MUTUAL FUND | 0.59% | 1.58 mio. | 2026-06-30 |
| American Century Capital… | 0.37% | 976 561 | 2026-06-30 |
| Bridge Builder Trust-Bri… | 0.36% | 967 100 | 2026-06-30 |
| Fidelity Concord Street… | 0.35% | 4.24 mio. | 2026-07-31 |
| VanEck ETF Trust-VanEck… | 0.35% | 938 561 | 2026-08-31 |
| Dodge & Cox Funds-Dodge… | 0.33% | 4.04 mio. | 2026-06-30 |
| iShares Trust-iShares MS… | 0.32% | 3.89 mio. | 2026-08-31 |
| Capital World Growth & I… | 0.3% | 3.67 mio. | 2026-06-30 |
| -Victory Pioneer Core Eq… | 0.3% | 799 487 | 2026-06-30 |
| Fidelity Covington Trust… | 0.3% | 797 184 | 2026-08-31 |
| NEW PERSPECTIVE FUND | 0.29% | 3.56 mio. | 2026-06-30 |
| Federated Hermes Eqy. Fd… | 0.29% | 3.48 mio. | 2026-07-31 |
| Bridge Builder Trust-Bri… | 0.29% | 3.44 mio. | 2026-06-30 |
| Pacer Advisors, Inc. | 0.1% | 1.16 mio. | 2026-06-30 |
| Generali Investments Cee… | 0% | 29 339 | 2026-06-30 |
| Paradigm Asset Managemen… | 0% | 19 200 | 2026-06-30 |
| Gamma Investing LLC | 0% | 58 | 2026-06-30 |
| L'Oréal | — | — | — |
